<DOC>
	<DOCNO>NCT01814137</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare efficacy insulin degludec/insulin aspart ( IDegAsp ) twice daily ( BID ) + insulin aspart ( IAsp ) daily ( OD ) versus basal bolus insulin degludec ( IDeg ) OD + IAsp three time day ( TID ) control glycaemia evaluate glycosylated haemoglobin ( HbA1c ) . The trial extension trial NN5401-3941 ( NCT01680341 ) .</brief_summary>
	<brief_title>A Randomised Trial Comparing Efficacy Safety After Intensification With Either Insulin Aspart Once Daily add-on Changing Basal Bolus Treatment With Insulin Degludec Insulin Aspart Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>HbA1c equal 7.0 % measure 26 week treatment NN54013941 ( NCT01680341 ) , central laboratory Uncontrolled untreated severe hypertension define systolic blood pressure equal 180 mmHg and/or diastolic blood pressure equal 100 mmHg Impaired liver function , define alanine aminotransferase ( ALAT ) aspartate aminotransferase ( ASAT ) equal 2.5 time upper limit normal Impaired renal function define serumcreatinine equal 125 micromol/L ( equal 1.4 mg/dL ) males equal 110 micromol/L ( equal 1.3 mg/dL ) female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>